Evolution of carfilzomib dose and schedule in patients with multiple myeloma: A historical overview-Reference-Cited by-同舟云学术

Evolution of carfilzomib dose and schedule in patients with multiple myeloma: A historical overview

Published:2014-07 Issue:6 Volume:40 Page:781-790
ISSN:0305-7372
Container-title:Cancer Treatment Reviews
language:en
Short-container-title:Cancer Treatment Reviews

Author:

Jakubowiak Andrzej J.

Publisher

Elsevier BV

Subject

Radiology, Nuclear Medicine and imaging,Oncology,General Medicine

Reference43 articles.

1. Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome;Demo;Cancer Res,2007

2. Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity;Meng;Proc Natl Acad Sci U S A,1999

3. The immunoproteasome: an emerging therapeutic target;Lee;Curr Top Med Chem,2011

4. A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies;O’Connor;Clin Cancer Res,2009

5. A phase I single-agent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma;Alsina;Clin Cancer Res,2012

Cited by 41 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Phase 1b study of carfilzomib with induction chemotherapy in pediatric relapsed/refractory acute lymphoblastic leukemia;Pediatric Blood & Cancer;2022-10-10

2. Combination of Second-Generation Proteasome Inhibitor Carfilzomib with Bortezomib in Four Different Breast Cancer Cell Lines;Anti-Cancer Agents in Medicinal Chemistry;2022-08-04

3. Are the Derived Indexes of Peripheral Whole Blood Cell Counts (NLR, PLR, LMR/MLR) Clinically Significant Prognostic Biomarkers in Multiple Myeloma? A Systematic Review And Meta-Analysis;Frontiers in Oncology;2021-11-23

4. Carfilzomib Promotes the Unfolded Protein Response and Apoptosis in Cetuximab-Resistant Colorectal Cancer;International Journal of Molecular Sciences;2021-07-01

5. Thrombotic microangiopathy in untreated myeloma patients receiving carfilzomib, cyclophosphamide and dexamethasone on the CARDAMON study;British Journal of Haematology;2021-03